12-05-2018 | Non-alcoholic fatty liver disease | Article
Lonardo A, Lugari S, Ballestri S et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1266-0
06-22-2018 | Gastroparesis | Review | Article
Krishnasamy S, Abell TL. Diabetes Ther (2018); 9 (Suppl 1): 1. doi: 10.1007/s13300-018-0454-9
06-12-2018 | Empagliflozin | Article
Kuchay MS et al. Diabetes Care 2018: dc180165. doi: 10.2337/dc18-0165
03-20-2018 | Diet | News
Researchers from the DiRECT trial have reported large positive effects on liver fat and insulin secretion among people who achieved type 2 diabetes remission in response to a very-low-calorie diet.
02-07-2018 | Risk factors | Highlight | News
Research shows that changes in markers of the metabolic syndrome and fatty liver disease are present more than 20 years before people receive a diagnosis of type 2 diabetes.
12-29-2017 | Nephropathy | Review | Article
Nat Rev Endocrinol 2017; 14: 99–114. doi: 10.1038/nrendo.2017.173
10-27-2017 | Risk factors | Review | Article
Shafqet M, Sharzehi K. Curr Treat Options Gastro 2017; 15: 508–519. doi: 10.1007/s11938-017-0163-x
10-06-2017 | Gastrointestinal disorders | Article
Kizilgul M et al. BMC Endocr Disord 2017; 17: 62. doi: 10.1186/s12902-017-0212-4
09-13-2017 | Diet | EASD 2017 | News
Results of a randomized trial suggest that patients with type 2 diabetes experience metabolic benefits from a hypocaloric diet regardless of whether it is low in fat or low in carbohydrate content.
08-03-2017 | Ipragliflozin | News
Results of a randomized trial suggest that the sodium-glucose cotransporter 2 inhibitor ipragliflozin has equivalent efficacy to pioglitazone for the treatment of patients with type 2 diabetes complicated by nonalcoholic fatty liver disease.
01-27-2017 | Gastroparesis | Book chapter | Article
Tansel A, Husain N. In: Managing Gastrointestinal Complications of Diabetes. Edited by Sellin J. Adis, Cham, 2017. doi: 10.1007/978-3-319-48662-8_3
01-21-2017 | Gastrointestinal disorders | Article
Yu D et al. Dig Dis Sci 2017; 62: 879–893. doi: 10.1007/s10620-017-4456-7
« Back to main page | Cardiovascular disease | Clinical trials | Continuous glucose monitoring | Devices and technology | Diabetes distress | Diabetes prevention | Diabetes self-management | Diabetic complications | Diabetic foot | Diagnosis | Diet and nutritional management | Gastrointestinal disorders | Genetics | Glycemic control | Guidelines | Healthcare systems | Hyperglycemia | Hypoglycemia | Lifestyle interventions | Medications | Mental health | Metabolic surgery | Obesity | Pathogenesis | Pediatrics | Physical activity | Quality of life | Retinopathy | Risk factors | Specific populations